 CAMBRIDGE, Mass., March 16, 2021 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, provided a business update for the fourth quarter and full year 2020. 